Fig. 1.
HBenvAg-specific proliferation.
PBMCs from XLA patients (A) or control subjects (B) were assessed by3H-thymidine incorporation 5 days after incubation with (solid bars) or without (open bars) 10 μg/mL HBenvAg. Responses by XLA patients' PBMCs at various antigen concentrations 1 month after vaccination appear in the inset and are expressed as mean ± SEM. Similar concentration-dependent responses were also obtained in controls (not shown). The assays were performed at different times before and after anti-HBV immunization as indicated. Each value was calculated as the mean cpm of triplicate determinations. Pt indicates patient; Ct, control subject.
